Topical Calcipotriol Plus 5-Fluorouracil Immunotherapy for Actinic Keratosis Treatment

• Marjan Azin,
• Andrew B. Mahon,
• Steven Isaacman,
• Julia E. Seaman,
• Isabel E. Allen,
• Michael Szarek,
• Lynn A. Cornelius,
• Shadmehr Demehri

Affiliations

Marjan Azin

Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cancer Immunology, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cancer Research, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Andrew B. Mahon

PHD Biosciences, San Diego, California, USA

Steven Isaacman

PHD Biosciences, San Diego, California, USA

Julia E. Seaman

Bay View Analytics, Oakland, California, USA

Isabel E. Allen

Bay View Analytics, Oakland, California, USA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA

Michael Szarek

School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; CPC Clinical Research, Aurora, Colorado, USA; Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA

Lynn A. Cornelius

Division of Dermatology, John T. Milliken Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA

Shadmehr Demehri

Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cancer Immunology, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cancer Research, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Corresponding author